CN110818634A - 甲磺酸乐伐替尼的精制方法 - Google Patents
甲磺酸乐伐替尼的精制方法 Download PDFInfo
- Publication number
- CN110818634A CN110818634A CN201810915404.1A CN201810915404A CN110818634A CN 110818634 A CN110818634 A CN 110818634A CN 201810915404 A CN201810915404 A CN 201810915404A CN 110818634 A CN110818634 A CN 110818634A
- Authority
- CN
- China
- Prior art keywords
- mesylate
- gas
- refining
- lervatinib
- refining method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 title claims abstract description 95
- 238000007670 refining Methods 0.000 title claims abstract description 75
- 238000000034 method Methods 0.000 title claims abstract description 74
- 238000004128 high performance liquid chromatography Methods 0.000 claims abstract description 28
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 27
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000002904 solvent Substances 0.000 claims abstract description 16
- 238000001816 cooling Methods 0.000 claims abstract description 14
- 239000003960 organic solvent Substances 0.000 claims abstract description 13
- 239000012043 crude product Substances 0.000 claims abstract description 12
- 125000005907 alkyl ester group Chemical group 0.000 claims abstract description 9
- 125000005233 alkylalcohol group Chemical group 0.000 claims abstract description 9
- 239000012046 mixed solvent Substances 0.000 claims abstract description 7
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims abstract description 6
- 150000002170 ethers Chemical class 0.000 claims abstract description 6
- 229960001518 levocarnitine Drugs 0.000 claims abstract description 6
- 239000005456 alcohol based solvent Substances 0.000 claims abstract description 3
- KLGVAUJELUIWKZ-UHFFFAOYSA-N dimethyl carbonate;ethane-1,2-diol Chemical group OCCO.COC(=O)OC KLGVAUJELUIWKZ-UHFFFAOYSA-N 0.000 claims abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 51
- 229960001429 lenvatinib mesylate Drugs 0.000 claims description 42
- HWLFIUUAYLEFCT-UHFFFAOYSA-N lenvatinib mesylate Chemical compound CS(O)(=O)=O.C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 HWLFIUUAYLEFCT-UHFFFAOYSA-N 0.000 claims description 42
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 33
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 150000005215 alkyl ethers Chemical class 0.000 claims description 12
- 238000005406 washing Methods 0.000 claims description 11
- 238000002425 crystallisation Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 150000004985 diamines Chemical class 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 230000008025 crystallization Effects 0.000 claims description 5
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 5
- LZDKZFUFMNSQCJ-UHFFFAOYSA-N 1,2-diethoxyethane Chemical compound CCOCCOCC LZDKZFUFMNSQCJ-UHFFFAOYSA-N 0.000 claims description 4
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical group COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 claims description 4
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 claims description 3
- 229940090181 propyl acetate Drugs 0.000 claims description 3
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 3
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 2
- 229940043232 butyl acetate Drugs 0.000 claims description 2
- 229940093499 ethyl acetate Drugs 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 2
- 229940011051 isopropyl acetate Drugs 0.000 claims description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000012535 impurity Substances 0.000 abstract description 33
- 239000000047 product Substances 0.000 abstract description 13
- 238000009776 industrial production Methods 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 36
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- 239000007864 aqueous solution Substances 0.000 description 18
- 239000012074 organic phase Substances 0.000 description 18
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 18
- 235000017557 sodium bicarbonate Nutrition 0.000 description 18
- BXWLVQXAFBWKSR-UHFFFAOYSA-N 2-methoxy-5-methylsulfonylbenzoic acid Chemical group COC1=CC=C(S(C)(=O)=O)C=C1C(O)=O BXWLVQXAFBWKSR-UHFFFAOYSA-N 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 238000003756 stirring Methods 0.000 description 13
- 239000000203 mixture Substances 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 12
- 229960003784 lenvatinib Drugs 0.000 description 11
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000011259 mixed solution Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 239000012065 filter cake Substances 0.000 description 7
- 238000001291 vacuum drying Methods 0.000 description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- -1 2-chloro-4-hydroxy phenyl Chemical group 0.000 description 4
- ZBTVNIDMGKZSGC-UHFFFAOYSA-N 4-chloro-7-methoxyquinoline-6-carboxamide Chemical compound C1=CC(Cl)=C2C=C(C(N)=O)C(OC)=CC2=N1 ZBTVNIDMGKZSGC-UHFFFAOYSA-N 0.000 description 4
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- QVPZNUIZEVRITP-UHFFFAOYSA-N 1-(2-chloro-4-hydroxyphenyl)-3-cyclopropylurea Chemical compound ClC1=CC(O)=CC=C1NC(=O)NC1CC1 QVPZNUIZEVRITP-UHFFFAOYSA-N 0.000 description 3
- PNLPXABQLXSICH-UHFFFAOYSA-N 4-amino-3-chlorophenol Chemical compound NC1=CC=C(O)C=C1Cl PNLPXABQLXSICH-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- ZSPLOATUDIRNAS-PPHPATTJSA-N levofloxacin mesylate Chemical compound CS(O)(=O)=O.C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 ZSPLOATUDIRNAS-PPHPATTJSA-N 0.000 description 3
- 229940098779 methanesulfonic acid Drugs 0.000 description 3
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 3
- LBDLNHLYEKFAHH-UHFFFAOYSA-N phenyl n-(2-chloro-4-hydroxyphenyl)carbamate Chemical compound ClC1=CC(O)=CC=C1NC(=O)OC1=CC=CC=C1 LBDLNHLYEKFAHH-UHFFFAOYSA-N 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- ZPNMMAVMJSCGET-UHFFFAOYSA-N (2-chloro-4-hydroxyphenyl)carbamic acid Chemical compound OC(=O)NC1=CC=C(O)C=C1Cl ZPNMMAVMJSCGET-UHFFFAOYSA-N 0.000 description 2
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 2
- HWDVTQAXQJQROO-UHFFFAOYSA-N cyclopropylazanide Chemical compound [NH-]C1CC1 HWDVTQAXQJQROO-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 2
- 229950009116 mevastatin Drugs 0.000 description 2
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- QBHBOFOMISIUEM-UHFFFAOYSA-N C1CC1NC(=O)C2=C(C=C(C=C2)O)Cl Chemical compound C1CC1NC(=O)C2=C(C=C(C=C2)O)Cl QBHBOFOMISIUEM-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- HOPSCVCBEOCPJZ-UHFFFAOYSA-N carboxymethyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC(O)=O HOPSCVCBEOCPJZ-UHFFFAOYSA-N 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000015799 differentiated thyroid carcinoma Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810915404.1A CN110818634B (zh) | 2018-08-13 | 2018-08-13 | 甲磺酸乐伐替尼的精制方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810915404.1A CN110818634B (zh) | 2018-08-13 | 2018-08-13 | 甲磺酸乐伐替尼的精制方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110818634A true CN110818634A (zh) | 2020-02-21 |
CN110818634B CN110818634B (zh) | 2021-11-30 |
Family
ID=69546820
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810915404.1A Active CN110818634B (zh) | 2018-08-13 | 2018-08-13 | 甲磺酸乐伐替尼的精制方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110818634B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111592536A (zh) * | 2020-06-04 | 2020-08-28 | 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) | 单环β-内酰胺化合物及其制备方法和应用 |
CN112654603A (zh) * | 2018-09-07 | 2021-04-13 | 因德纳有限公司 | 乐伐替尼的制备方法 |
WO2022022367A1 (zh) * | 2020-07-28 | 2022-02-03 | 药源药物化学(上海)有限公司 | 一种高纯度结晶的制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016184436A1 (zh) * | 2015-05-21 | 2016-11-24 | 苏州晶云药物科技有限公司 | 乐伐替尼甲磺酸盐的新晶型及其制备方法 |
EP3299360A1 (en) * | 2016-09-21 | 2018-03-28 | INDENA S.p.A. | Crystal forms of lenvatinib |
WO2018122780A1 (en) * | 2016-12-29 | 2018-07-05 | Dr. Reddy’S Laboratories Limited | Solid state forms of lenvatinib mesylate |
WO2018196687A1 (zh) * | 2017-04-25 | 2018-11-01 | 苏州科睿思制药有限公司 | 乐伐替尼甲磺酸盐的新晶型及其制备方法 |
-
2018
- 2018-08-13 CN CN201810915404.1A patent/CN110818634B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016184436A1 (zh) * | 2015-05-21 | 2016-11-24 | 苏州晶云药物科技有限公司 | 乐伐替尼甲磺酸盐的新晶型及其制备方法 |
EP3299360A1 (en) * | 2016-09-21 | 2018-03-28 | INDENA S.p.A. | Crystal forms of lenvatinib |
WO2018122780A1 (en) * | 2016-12-29 | 2018-07-05 | Dr. Reddy’S Laboratories Limited | Solid state forms of lenvatinib mesylate |
WO2018196687A1 (zh) * | 2017-04-25 | 2018-11-01 | 苏州科睿思制药有限公司 | 乐伐替尼甲磺酸盐的新晶型及其制备方法 |
Non-Patent Citations (1)
Title |
---|
武汉大学化学与分子科学学院实验中心: "《基础有机化学实验》", 31 July 2014, 武汉大学出版社 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112654603A (zh) * | 2018-09-07 | 2021-04-13 | 因德纳有限公司 | 乐伐替尼的制备方法 |
CN112654603B (zh) * | 2018-09-07 | 2024-05-03 | 意迪那有限公司 | 乐伐替尼的制备方法 |
CN111592536A (zh) * | 2020-06-04 | 2020-08-28 | 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) | 单环β-内酰胺化合物及其制备方法和应用 |
CN111592536B (zh) * | 2020-06-04 | 2023-11-03 | 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) | 单环β-内酰胺化合物及其制备方法和应用 |
WO2022022367A1 (zh) * | 2020-07-28 | 2022-02-03 | 药源药物化学(上海)有限公司 | 一种高纯度结晶的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN110818634B (zh) | 2021-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110818634B (zh) | 甲磺酸乐伐替尼的精制方法 | |
US9216947B2 (en) | Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs | |
JP2007302658A (ja) | イマチニブメシレートの多形フォーム及び新規結晶フォーム及び非晶フォーム並びにフォームαの調製方法 | |
EP2311794B1 (en) | Polymorphs of bromfenac sodium and methods for preparing bromfenec sodium polymorphs | |
CN101993447A (zh) | 一种人工合成普拉格雷的方法 | |
EP3694843B1 (en) | New salt and solid state forms of escitalopram | |
US11242340B2 (en) | Crystal forms of demethyleneberberine hydrochloride and preparation method therefor | |
AU2003206755B2 (en) | Solid salts benzazepine compounds and their use in the preparation of pharmaceuticals compounds | |
TW201546045A (zh) | 新穎結晶性芳烷基胺化合物及其製造方法 | |
KR101806782B1 (ko) | 고순도 바제독시펜 아세테이트의 제조방법 | |
CN113816914B (zh) | 一种劳拉西泮中间体的制备方法 | |
CN110467600A (zh) | 一种德拉沙星葡甲胺盐晶型l及其制备方法 | |
CN1740138A (zh) | 从苯酐硝化制备3-硝基邻苯二甲酸的反应母液中制备4-硝基邻苯二甲酸的方法 | |
US7368593B1 (en) | Method of selective esterification | |
KR101341449B1 (ko) | 디메틸 테레프탈레이트 제조공정의 부산물로부터 p-클로로메틸벤조산 및 벤조산의 제조방법 | |
CN108203396B (zh) | 一种脑啡肽酶抑制剂的合成 | |
CN110885300A (zh) | 羟苯磺酸酯类化合物的合成工艺 | |
JP6894489B2 (ja) | ベラプロスト−314d・一水和物結晶及びその製造方法 | |
WO2017031994A1 (zh) | 曲沙他滨的合成及其晶型 | |
US20230286898A1 (en) | Method for the purification of vilanterol trifenatate | |
CN114524769B (zh) | 塞来昔布-卡马西平共晶、制备方法、药物组合物和应用 | |
CA2068429C (en) | Process for the purification of 7-chloroquinoline-8-carboxylic acids | |
CN116554014A (zh) | 一种非诺贝特及其杂质的制备方法 | |
CN114437026A (zh) | 一种低组合物杂质的苹果酸奈诺沙星原料药及其制备方法 | |
CN105142626A (zh) | Vsn16的结晶形态 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20211029 Address after: 201306 floor 3 and 4, Building 29, No. 356, ZHENGBO Road, Lingang xinpian District, China (Shanghai) pilot Free Trade Zone, Fengxian District, Shanghai Applicant after: Shanghai xinlitai Pharmaceutical Co.,Ltd. Address before: Room A679-04, Building No. 2, 351 GuoShoujing Road, China (Shanghai) Free Trade Pilot Area, Pudong New Area, Shanghai, 201203 Applicant before: SHANGHAI BOCIMED PHARMACEUTICAL Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Refining Method of Levatinib Mesylate Effective date of registration: 20230807 Granted publication date: 20211130 Pledgee: Bank of Shanghai Limited by Share Ltd. Pudong branch Pledgor: Shanghai xinlitai Pharmaceutical Co.,Ltd. Registration number: Y2023310000446 |